Advertisement

Pharmacy World and Science

, Volume 16, Issue 3, pp 149–153 | Cite as

Urinary concentrations of fosfomycin after a single 3 g dose of fosfomycin to elderly nursing-home patients

  • R. Janknegt
  • P. M. Hooymans
  • G. T. J. Fabius
  • M. K. E. Nohlmans-Paulssen
  • C. Machielsen
  • J. Boogaard-van den Born
  • J. Rang
  • C. A. M. Smits
  • M. E. Willems-Thissen
  • A. Krommenhoek
Articles

Abstract

The urinary concentrations of fosfomycin in 7 elderly patients with impaired renal function (mean creatinine clearance 40 ml/min) were studied after a single oral dose of 3 g fosfomycin as the trometamol salt. Urine samples were collected as 12 h portions for 84 h. Urinary concentrations of fosfomycin were 1,383 mg/l (range 314 to 4,200 mg/l) in the first 12 h and gradually declined to 165 mg/l (range 65 to 365 mg/l) between 36 and 48 h. 37% of the oral dose was recovered in the urine unchanged after 84 h, but a wide range (15–60%) in urinary recovery was observed. The elimination half-lives in the patients (estimated from the renal excretion profile of fosfomycin) ranged between 7 and 24 h. These data suggest that the urinary levels obtained in this patient population exceed the minimum inhibiting concentration of the usual pathogens involved in uncomplicated cystitis for at least 48 h. After 24 h the urinary concentrations of fosfomycin are higher than those reported for healthy young subjects.

Keywords

Aged Clearance, renal Concentration, urine Fosfomycin Kidney diseases Pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fillastre JP, Leroy A, Humbert G, Borsa F, Josse S. Comparative pharmacokinetics of fosfomycin trometamol versus calcium fosfomycin in elderly subjects and uraemic patients. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basle: Karger, 1988:143–56.Google Scholar
  2. 2.
    Segre G, Bianchi E, Cataldi A, Zannini G. Pharmacokinetic profile of fosfomycin trometamol. Eur Urol 1987;13 suppl 1:56–63.PubMedGoogle Scholar
  3. 3.
    Wilson P, Williams JD, Roland E. Comparative pharmacokinetics of fosfomycin trometamol, sodium fosfomycin and calcium fosfomycin in humans. In: Neu HC, Williams JS, editors. New trends in urinary tract infections. Basle: Karger, 1988:136–42.Google Scholar
  4. 4.
    Jeliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604–5.PubMedGoogle Scholar
  5. 5.
    Janknegt R, Boogaard-van den Born J, Hameleers BAMJ, Hooymans PM, Rang J, Smits CAM, et al. Pharmacokinetics of amoxycillin in elderly in-patients. Pharm Weekbl Sci 1992;14(1):27–9.PubMedGoogle Scholar
  6. 6.
    O'Connell MB, Dwinell AM, Bannick-Mohrland SD. Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients. Ann Pharmacother 1992;26:627–35.PubMedGoogle Scholar
  7. 7.
    Bergan T, Mastropaolo G, Di Mario F, Naccarato R. Pharmacokinetics of fosfomycin and influence of cimetidine and metoclopramide on the bioavailability of fosfomycin trometamol. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basle: Karger, 1988:157–66.Google Scholar
  8. 8.
    Pinasi C, Albini E, Marca G. Correlation between bactericidal activity of fosfomycin trometamol in anin vitro model of the urinary bladder and susceptibility testing. Eur Urol 1987;13 suppl 1:80–5.PubMedGoogle Scholar
  9. 9.
    Bergogne-Berezin E, Müller-Serieys C, Joly-Guillou ML, Dronne N. Trometamol-fosfomycin bioavailability and food-drug interaction. Eur Urol 1987;13 suppl 1:64–8.PubMedGoogle Scholar
  10. 10.
    Lerner SA, Price S, Kulkarni S. Microbiological studies of fosfomycin trometamol against urinary isolates in vitro. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basle: Karger, 1988:121–9.Google Scholar
  11. 11.
    Greenwood D, Coyle S, Andrew J. The trometamol salt of fosfomycin: microbiological evaluation. Eur Urol 1987;13 suppl 1:69–75.PubMedGoogle Scholar
  12. 12.
    Barry AL, Fuchs PC.In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrob Agents Chemother 1991;35:1235–8.PubMedGoogle Scholar
  13. 13.
    Reeves DS, Holt HA, Bywater MJ.In vitro study of fosfomycin trometamol. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basle: Karger, 1988:224–31.Google Scholar
  14. 14.
    Wise R, Andrews JM. Fosfomycin trometamol: anin vitro study. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basle: Karger, 1988:232–41.Google Scholar
  15. 15.
    King A, Philips I. Comparativein vitro activity of fosfomycin trometamol against urinary tract pathogens. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basle: Karger, 1988:242–9.Google Scholar
  16. 16.
    Naber KG, Thyroff-Friesinger U. Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single-dose therapy with fosfomycin trometamol versus ofloxacin/cotrimoxazole. Infection 1992;20 suppl 4:S296-S301.PubMedGoogle Scholar
  17. 17.
    Wiedemann B, Groos M. Antibacterial activity of fosfomycin in the urine after simulation of oral doses in a pharmacodynamicin-vitro model. Eur Urol 1987;13 suppl 1:76–9.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for the Advancement of Pharmacy 1994

Authors and Affiliations

  • R. Janknegt
    • 1
  • P. M. Hooymans
    • 1
  • G. T. J. Fabius
    • 2
  • M. K. E. Nohlmans-Paulssen
    • 2
  • C. Machielsen
    • 2
  • J. Boogaard-van den Born
    • 3
  • J. Rang
    • 3
  • C. A. M. Smits
    • 3
  • M. E. Willems-Thissen
    • 3
  • A. Krommenhoek
    • 3
  1. 1.Department of Clinical PharmacyMaasland Hospital Sittard/GeleenMB Sittardthe Netherlands
  2. 2.Department of Medical MicrobiologyMaasland Hospital Sittard/Geleenthe Netherlands
  3. 3.Nursing Home St. OdiliaHK Geleenthe Netherlands

Personalised recommendations